Why the study?
Does adding dipyridamole to aspirin reduce vascular events in patients after ischaemic stroke or TIA?
Does adding dipyridamole to aspirin reduce vascular events in patients after ischaemic stroke or TIA?
Adding dipyridamole to aspirin is superior to aspirin alone for secondary prevention of vascular events after ischemic stroke or TIA.
Answers are grounded in this paper and cite their sources.
Supports dipyridamole addition to aspirin for post-stroke/TIA secondary prevention; leaves open confirmation in contemporary randomized trials.
After an ischaemic stroke or transient ischaemic attack (TIA), patients are at high risk of subsequent stroke and other vascular events, such as myocardial infarction. Strategies to prevent vascular events (stroke, myocardial infarction, or vascular death) in such patients include using aspirin, which is the most widely tested single antiplatelet drug for this purpose.1 2 Good evidence now exists, however, that adding dipyridamole to aspirin further reduces the risk in patients who have had an ischaemic stroke or transient ischaemic attack. #### KEY POINTS Sources of evidence are shown in the box.1 2 3 #### Sources of evidence I identified relevant randomised trials and systematic reviews from the sources shown:
No takes yet. Share an insight, caveat, or question.
Cathie Sudlow (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: